BioSpace News Archive

After 21 years as Arthritis Research Canada/Arthrite-recherche Canada’s scientific director, world-renowned scientist and rheumatologist, Dr. John Esdaile is handing the leadership reins over to Dr. Diane Lacaille MD,CM, MHSc, FRCPC.

ILIAS Biologics Inc. (the “Company” or “ILIAS”), a global leader in exosome-based therapeutics, announced today that the Company has been granted a key exosome engineering patent by the United States Patent and Trademark Office (USPTO).

Company Seeks to Partner with Health Systems to Unlock Value in Rehabilitation Operations, Promote Continuity of Care, and Improve Patient Outcomes

Orthopaedic surgeons at Crystal Clinic Orthopaedic Center are at the forefront of developing advanced, minimally invasive techniques for patients and providing training to other surgeons around the globe in their use.

Aesculap Implant Systems, LLC today announced that National Imaging Associates (NIA), a Magellan Health Company, has updated its “Clinical Guidelines for Medical Necessity for Musculoskeletal and Surgery” to include a medical necessity recommendation for Lumbar Total Disc Replacement (TDR), including the latest generation activL® Artificial Disc.

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a reduction in workforce of approximately 30% of its head count to focus on development of its first-in-class PDK1 inhibitor SNS-510.

Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that it has appointed biopharmaceutical industry veteran Thomas M. Soloway to its Board of Directors effective July 2, 2020.

Aeterna Zentaris Inc., a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, announced the closing of its previously announced public offering of 17,544,516 units at a price to the public of $0.45 per unit and 9,122,150 pre-funded units at a price to the public of $0.4499 per pre-funded unit.

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company pioneering targeted C3 therapies, announced that the company approved the grant of equity awards to three new employees with a grant date of July 1, 2020, as an equity inducement award outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.